• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

供给侧成本效益阈值:循证政策的问题。

Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy.

机构信息

Office of Health Economics, London, UK.

Imperial College London, London, UK.

出版信息

Appl Health Econ Health Policy. 2022 Sep;20(5):651-667. doi: 10.1007/s40258-022-00730-3. Epub 2022 Jun 7.

DOI:10.1007/s40258-022-00730-3
PMID:35668345
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9385803/
Abstract

There is growing interest in cost-effectiveness thresholds as a tool to inform resource allocation decisions in health care. Studies from several countries have sought to estimate health system opportunity costs, which supply-side cost-effectiveness thresholds are intended to represent. In this paper, we consider the role of empirical estimates of supply-side thresholds in policy-making. Recent studies estimate the cost per unit of health based on average displacement or outcome elasticity. We distinguish the types of point estimates reported in empirical work, including marginal productivity, average displacement, and outcome elasticity. Using this classification, we summarise the limitations of current approaches to threshold estimation in terms of theory, methods, and data. We highlight the questions that arise from alternative interpretations of thresholds and provide recommendations to policymakers seeking to use a supply-side threshold where the evidence base is emerging or incomplete. We recommend that: (1) policymakers must clearly define the scope of the application of a threshold, and the theoretical basis for empirical estimates should be consistent with that scope; (2) a process for the assessment of new evidence and for determining changes in the threshold to be applied in policy-making should be created; (3) decision-making processes should retain flexibility in the application of a threshold; and (4) policymakers should provide support for decision-makers relating to the use of thresholds and the implementation of decisions stemming from their application.

摘要

人们对成本效益阈值越来越感兴趣,将其作为医疗保健资源分配决策的工具。来自多个国家的研究试图估计卫生系统机会成本,而供应方成本效益阈值旨在代表这种成本。本文考虑了实证估计供应方阈值在决策中的作用。最近的研究根据平均替代或结果弹性来估计单位健康的成本。我们区分了实证工作中报告的点估计类型,包括边际生产力、平均替代和结果弹性。使用这种分类方法,我们根据理论、方法和数据总结了当前阈值估计方法的局限性。我们强调了从阈值的替代解释中产生的问题,并为那些在证据基础尚不完善或不完整的情况下寻求使用供应方阈值的政策制定者提供了建议。我们建议:(1)政策制定者必须明确界定阈值应用的范围,实证估计的理论基础应与其一致;(2)应创建一个评估新证据和确定政策制定中应用的阈值变化的过程;(3)决策过程应保持对阈值应用的灵活性;(4)政策制定者应支持决策者使用阈值和实施应用阈值产生的决策。

相似文献

1
Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy.供给侧成本效益阈值:循证政策的问题。
Appl Health Econ Health Policy. 2022 Sep;20(5):651-667. doi: 10.1007/s40258-022-00730-3. Epub 2022 Jun 7.
2
Informing a cost-effectiveness threshold for Saudi Arabia.确定沙特阿拉伯的成本效益阈值。
J Med Econ. 2023 Jan-Dec;26(1):128-138. doi: 10.1080/13696998.2022.2157141.
3
Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.英国国家卫生与临床优化研究所成本效益阈值的估计方法。
Health Technol Assess. 2015 Feb;19(14):1-503, v-vi. doi: 10.3310/hta19140.
4
The use of economic evaluations in NHS decision-making: a review and empirical investigation.国民健康服务体系决策中经济评估的应用:一项综述与实证研究
Health Technol Assess. 2008 Apr;12(7):iii, ix-x, 1-175. doi: 10.3310/hta12070.
5
Estimating a cost-effectiveness threshold for health care decision-making in South Africa.估算南非医疗保健决策的成本效益阈值。
Health Policy Plan. 2020 Jun 1;35(5):546-555. doi: 10.1093/heapol/czz152.
6
Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures.确定实现全民健康覆盖的效率路径:基于预期寿命和卫生支出增长的 174 个国家的成本效益阈值。
Lancet Glob Health. 2023 Jun;11(6):e833-e842. doi: 10.1016/S2214-109X(23)00162-6.
7
The Arthroplasty Candidacy Help Engine tool to select candidates for hip and knee replacement surgery: development and economic modelling.人工关节置换候选帮助引擎工具选择髋关节和膝关节置换手术的候选者:开发和经济建模。
Health Technol Assess. 2019 Jun;23(32):1-216. doi: 10.3310/hta23320.
8
Objectives, Budgets, Thresholds, and Opportunity Costs-A Health Economics Approach: An ISPOR Special Task Force Report [4].目标、预算、阈值与机会成本——一种卫生经济学方法:一份药物经济学与结果研究协会(ISPOR)特别工作组报告[4]
Value Health. 2018 Feb;21(2):140-145. doi: 10.1016/j.jval.2017.12.008.
9
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
10
Generalisability in economic evaluation studies in healthcare: a review and case studies.医疗保健经济评估研究中的可推广性:综述与案例研究
Health Technol Assess. 2004 Dec;8(49):iii-iv, 1-192. doi: 10.3310/hta8490.

引用本文的文献

1
Guidelines for the use of economic evaluation to inform policies around access to treatment for kidney failure.利用经济评估为肾衰竭治疗可及性相关政策提供信息的指南。
Nat Rev Nephrol. 2025 Sep 11. doi: 10.1038/s41581-025-01000-w.
2
Return on investment of rapid ICU workforce upskilling: an economic and cost-effectiveness analysis.快速提升重症监护病房工作人员技能的投资回报率:一项经济与成本效益分析。
Intensive Care Med. 2025 Aug;51(8):1453-1461. doi: 10.1007/s00134-025-08033-6. Epub 2025 Jul 21.
3
Supervised Exercise for Patients With Metastatic Breast Cancer: A Cost-Utility Analysis Alongside the PREFERABLE-EFFECT Randomized Controlled Trial.转移性乳腺癌患者的监督运动:一项与PREFERABLE-EFFECT随机对照试验并行的成本效用分析。
J Clin Oncol. 2025 Apr 10;43(11):1325-1336. doi: 10.1200/JCO-24-01441. Epub 2025 Jan 13.
4
Establishing cost-effectiveness threshold in China: a community survey of willingness to pay for a healthylife year.在中国建立成本效益阈值:一项关于健康生活年支付意愿的社区调查。
BMJ Glob Health. 2024 Jan 9;9(1):e013070. doi: 10.1136/bmjgh-2023-013070.
5
Resource allocation in public sector programmes: does the value of a life differ between governmental departments?公共部门项目中的资源分配:不同政府部门之间生命的价值是否存在差异?
Cost Eff Resour Alloc. 2023 Dec 15;21(1):96. doi: 10.1186/s12962-023-00500-5.
6
Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial.每月一次缓释丁丙诺啡与每日标准护理药物相比的优越性和成本效益:一项实用、平行组、开放标签、多中心、随机、对照的3期试验。
EClinicalMedicine. 2023 Nov 17;66:102311. doi: 10.1016/j.eclinm.2023.102311. eCollection 2023 Dec.
7
The Value of Health in a Cost-Effectiveness Analysis: Theory Versus Practice.健康的价值在成本效益分析中的体现:理论与实践。
Pharmacoeconomics. 2023 Jun;41(6):607-617. doi: 10.1007/s40273-023-01265-8. Epub 2023 Apr 18.
8
A Model-Based Estimate of the Cost-Effectiveness Threshold in Germany.基于模型的德国成本效益阈值估算。
Appl Health Econ Health Policy. 2023 Jul;21(4):627-635. doi: 10.1007/s40258-023-00803-x. Epub 2023 Apr 11.
9
How Much Should be Invested in Lung Care Across the WHO European Region? Applying a Monetary Value to Disability-Adjusted Life-Years Within the International Respiratory Coalition's Lung Facts.在世界卫生组织欧洲区域,应该为肺部护理投入多少资金?在国际呼吸联盟的“肺部事实”中,用残疾调整生命年来衡量。
Appl Health Econ Health Policy. 2023 Jul;21(4):547-558. doi: 10.1007/s40258-023-00802-y. Epub 2023 Apr 11.

本文引用的文献

1
Resource allocation in public sector programmes: does the value of a life differ between governmental departments?公共部门项目中的资源分配:不同政府部门之间生命的价值是否存在差异?
Cost Eff Resour Alloc. 2023 Dec 15;21(1):96. doi: 10.1186/s12962-023-00500-5.
2
Are Estimates of the Health Opportunity Cost Being Used to Draw Conclusions in Published Cost-Effectiveness Analyses? A Scoping Review in Four Countries.健康机会成本的估算是否被用于在已发表的成本效益分析中得出结论?四个国家的范围综述
Appl Health Econ Health Policy. 2022 May;20(3):337-349. doi: 10.1007/s40258-021-00707-8. Epub 2021 Dec 29.
3
Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates.医疗保健系统所产生的健康边际成本的经验估计:来自国家层面估计的方法学考虑。
Pharmacoeconomics. 2022 Jan;40(1):31-43. doi: 10.1007/s40273-021-01087-6. Epub 2021 Sep 29.
4
Avoiding Opportunity Cost Neglect in Cost-Effectiveness Analysis for Health Technology Assessment.在卫生技术评估的成本效益分析中避免机会成本忽视
Appl Health Econ Health Policy. 2022 Jan;20(1):13-18. doi: 10.1007/s40258-021-00679-9. Epub 2021 Sep 1.
5
Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems.估算品牌药品的价值在制药企业和接受医疗系统服务的患者之间的分配情况。
Health Econ. 2021 Nov;30(11):2649-2666. doi: 10.1002/hec.4393. Epub 2021 Aug 2.
6
What next after GDP-based cost-effectiveness thresholds?基于国内生产总值的成本效益阈值之后还有什么?
Gates Open Res. 2020 Nov 30;4:176. doi: 10.12688/gatesopenres.13201.1. eCollection 2020.
7
On the role of cost-effectiveness thresholds in healthcare priority setting.关于成本效益阈值在医疗保健优先级设置中的作用。
Int J Technol Assess Health Care. 2021 Jan 25;37:e23. doi: 10.1017/S0266462321000015.
8
A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States.美国成本效益分析的健康机会成本阈值。
Ann Intern Med. 2021 Jan;174(1):25-32. doi: 10.7326/M20-1392. Epub 2020 Nov 3.
9
Health Opportunity Costs: Assessing the Implications of Uncertainty Using Elicitation Methods with Experts.健康机会成本:运用向专家请教的方法评估不确定性的影响。
Med Decis Making. 2020 May;40(4):448-459. doi: 10.1177/0272989X20916450. Epub 2020 May 22.
10
Estimating a cost-effectiveness threshold for health care decision-making in South Africa.估算南非医疗保健决策的成本效益阈值。
Health Policy Plan. 2020 Jun 1;35(5):546-555. doi: 10.1093/heapol/czz152.